“By embracing a hyperconverged infrastructure from Lenovo and Nutanix, we’ve demolished the barriers to digital transformation. Looking ahead, we plan to use the platform to build next-generation big-data analytics technologies—empowering QR Pharmaceuticals to develop innovative treatments that benefit the whole world."
Wuhan Qirui Pharmaceutical Co., Ltd. (hereafter referred to as QR Pharmaceuticals) is based at the Miaoshan Medical Park, Donghu Development Zone in Wuhan, China, and is part of the Wuhan Qirui Technology Development Co., Ltd. Group.
QR Pharmaceuticals has led innovative research projects on cerebrovascular, digestive, and respiratory diseases, and fungal infections in accordance with international standards. The company has undertaken research as part of the National Key New Drug Creation Program—a drug development program sponsored by China’s Ministry of Science and Technology. QR Pharmaceuticals has also conducted more than 40 research projects for the National Development and Reform Commission and the Ministry of Industry and Information Technology.
Fill out this form and a member of the Customer Marketing Team will contact you.